Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|July 1, 1994
Erythropoietin response to blood loss in hemodialysis patients in blunted but preservedR P Ross, J B McCrea, A BesarabDICP : the Annals of Pharmacotherapy|January 1, 1989
Allergic reaction to antipyrine, a marker of hepatic enzyme activityJ B McCrea, P H Vlasses, M L RocciPharmacotherapy|January 1, 1990
Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 daysJ B McCrea, P H Vlasses, T J Franz, et al.Clinical Pharmacology and Therapeutics|December 1, 1995
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humansM W Lo, M R Goldberg, J B McCrea, et al.Clinical Pharmacology and Therapeutics|March 1, 1996
Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174M R Goldberg, M W Lo, P J Deutsch, et al.Journal of Clinical Pharmacology|June 1, 1993
Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patientsJ B McCrea, R J Fruncillo, S D Holland, et al.Journal of the American Society of Nephrology : JASN|March 1, 1992
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administrationA Besarab, K K Flaharty, A J Erslev, et al.Journal of Clinical Pharmacology|December 1, 1995
Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazideJ B McCrea, M W Lo, L Tomasko, et al.International Journal of Clinical Pharmacology and Therapeutics|August 5, 2000
Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulationLo M-W, J B McCrea, C R Shadle, et al.Pageof 1